iBio (IBIO) Long-Term Debt Repayments (2023 - 2024)

iBio's (IBIO) quarterly Long-Term Debt Repayments came in at $1.1 million in Q2 2024, up 147.02% on a QoQ basis from $436000.0 in Q3 2023.

iBio (IBIO) Long-Term Debt Repayments (2023 - 2024) Analysis & Trends

iBio (IBIO) has 2 years of Long-Term Debt Repayments data on file, last reported at $1.1 million in Q2 2024.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $1.1 million in Q2 2024; TTM through Jun 2024 was $1.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $1.5 million, down 83.76% from the prior year.
Long-Term Debt Repayments for Q2 2024 stood at $1.1 million, up from $436000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for IBIO reached as high as $1.1 million in Q2 2024 and fell as low as $436000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	65,899.61 Bn	65,899.33 Bn	-	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-
4	BeOne Medicines	471.67 Bn	466.88 Bn	1.35 Bn	7.64 Mn
5	Vertex Pharmaceuticals	122.32 Bn	115.07 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	70.04 Bn	61.29 Bn	3.31 Bn	-
7	Belite Bio	62.06 Bn	62.06 Bn	-	-
8	Argenx Se	55.93 Bn	50.74 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.55 Bn	34.54 Bn	959.66 Mn	-
10	iBio	166.84 Mn	166.84 Mn	-	-

Download Data